Biohaven's clinical development program for troriluzole has spanned over eight years, including long-term safety data and the first large-scale, multi-center registrational trials in SCA.

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...

Non-CGRP assets including troriluzole for obsessive compulsive ... will transfer to Pfizer's internal pipeline. Shares in Biohaven rocketed more than 70% to more than $142 after the takeover ...

Biohaven’s lead clinical asset ... topline results from its pivotal Phase 3 study which demonstrated that Troriluzole dosed at 200mg daily slowed disease progression of 50-70%, which the ...

Troriluzole 200 mg dosed orally ... BHV-1300 and BHV-1310 are IgG degraders; Biohaven introduced next generation TRAPTM (Targeted Removal of Aberrant Protein) degraders, which are highly selective ...

Swiss National Bank raised its stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 12.2% during the 4th quarter, ...

Cibc World Markets Corp purchased a new stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) in the 4th quarter, ...

Biohaven reported Q4 earnings on March 3 and ... the primary focus for the stock to remain on upcoming FDA action on Troriluzole for Spinocerebellar Ataxia this summer. Effectively assess a ...

Based on FDA Priority Review timelines and, if ultimately approved, Biohaven is prepared to commercialize troriluzole for SCA in the US in 2025. The Company had previously achieved positive ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's ... balance of portfolio: Troriluzole (novel glutamate ...